Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of M3814 and to see how well it
works when given together with radiation therapy in treating patients with pancreatic cancer
that cannot be removed by surgery and has not spread to other parts of the body (localized).
M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a
shorter period of time and may kill more tumor cells and have fewer side effects. Giving
M3814 and hypofractionated radiation therapy together may work better than radiation therapy
alone in the treatment of patients with localized pancreatic cancer.